Mads Axelsen

Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials

Kenneth D Boffard, Bruno Riou, Brian Warren et al. · The Journal of Trauma: Injury, Infection, and Critical Care · 2005 · 785 citations

Medicine, Pharmacotherapy, Surgery +16

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

John E. Blundell, Graham Finlayson, Mads Axelsen et al. · Diabetes Obesity and Metabolism · 2017 · 634 citations · Full text

Agriculture, Nutritional Sciences, Pharmacology +17

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou et al. · The Lancet Diabetes & Endocrinology · 2017 · 443 citations

Medicine, Endocrinology, Pharmacology +10

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

Julie Hjerpsted, Anne Flint, Ashley Brooks et al. · Diabetes Obesity and Metabolism · 2017 · 231 citations · Full text

Medicine, Endocrinology, Pharmacology +15

Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin

Kjeld Hermansen, Sten Madsbad, Hans Perrild et al. · Diabetes Care · 2001 · 174 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17